Efficacy News and Research

RSS

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.

21 Aug 2012

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical phase Ib trial of the company's candidate drug (CD) MIV-711 has commenced.

21 Aug 2012

New attack on arthritis pain

A research team from the University of Melbourne is working on a new therapy that can potentially control the pain caused by diseases such as rheumatoid arthritis and osteoarthritis.

21 Aug 2012

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.

21 Aug 2012

HPV genotype may alter chemoradiotherapy outcome

Human papillomavirus genotype predicts whether patients with cervical cancer will benefit from concurrent chemoradiation therapy, study findings suggest.

20 Aug 2012

Physiotherapy beneficial for Parkinson’s patients

Results from a systematic review and meta-analysis published in the BMJ suggest that physiotherapy interventions benefit Parkinson’s disease (PD) patients, at least in the short term.

20 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Curcumin shows promise in fighting devastating viruses

The popular spice turmeric packs more than just flavor - it shows promise in fighting devastating viruses, Mason researchers recently discovered.

17 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Be ‘medicinewise’ with cough and cold medicines in young children

NPS MedicineWise is urging parents and health professionals to heed the advice from the Therapeutic Goods Administration (TGA) this week restricting the use of cough and cold medicines to treat young children amidst concerns they have limited efficacy and may even be harmful.

16 Aug 2012

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.

16 Aug 2012

Rivaroxaban effective in children

Laboratory tests show no significant differences in rivaroxaban efficacy across children aged from 28 days to 16 years, researchers report.

16 Aug 2012

Rivaroxaban effective in children

Laboratory tests show no significant differences in rivaroxaban efficacy across children aged from 28 days to 16 years, researchers report.

16 Aug 2012

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine.

16 Aug 2012

APS’ Sharon S. Keller Chronic Pain Research Program to award $150,000 for eligible members

The American Pain Society (APS) announced today it is accepting applications for research grants from the newly established Sharon S. Keller Chronic Pain Research Program.

16 Aug 2012

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

16 Aug 2012

Combination of exercise and S-nitrosoglutathione improves recovery from stroke

In a study published in the current issue of Restorative Neurology and Neuroscience scientists report that a therapy combining exercise with the neurovascular protective agent S-nitrosoglutathione (GSNO) improved recovery from stroke in a rat model. GSNO is a compound found naturally in the body and it has no known side effects or toxicity.

16 Aug 2012

Kessler Foundation investigates Ekso's new capabilities for autonomous use by people with SCI

Kessler Foundation has begun testing the upgraded Ekso in individuals unable to walk due to spinal cord injury. Ekso, a wearable, battery-powered robotic exoskeletal device, has been undergoing clinical investigation at Kessler since October 2011, when the research team received the second commercial unit distributed by Ekso Bionics.

15 Aug 2012

Trial to test efficacy of NeuRx Diaphragm Pacing System in people with Lou Gehrig's disease

The Muscular Dystrophy Association (MDA) and The ALS Association today announced a joint commitment to provide funding for a phase 2 clinical trial that will test efficacy of the NeuRx Diaphragm Pacing System (DPS) in people with amyotrophic lateral sclerosis (ALS).

15 Aug 2012